Mustang Bio’s $40 Million Public Offering


Alston & Bird advised Mustang Bio Inc.

Mustang Bio Inc.,a clinical-stage biopharmaceutical company, has closed a public offering of common stock aimed at raising approximately $40 million.

The company will use the net proceeds from the offering for continued product development; potential in-license, acquisition, and development and commercialization of other pharmaceutical products; and general corporate purposes.

Based in Worcester, MA, and listed on Nasdaq, Mustang focuses on acquiring, developing, and commercializing novel immunotherapies for cancers and rare genetic diseases.

The Alston & Bird team was led by partner Mark McElreath (Picture), senior associate Gerard Hart, and associate Joel Jung (Corporate) and partner Natalie Clayton and associate Ravi Shah (Intellectual Property).

Involved fees earner: Natalie Clayton – Alston & Bird LLP; Gerard Hart Jr. – Alston & Bird LLP; Mark McElreath – Alston & Bird LLP; Ravi Shah – Alston & Bird LLP;

Law Firms: Alston & Bird LLP;

Clients: Mustang Bio;

Author: Ambrogio Visconti